SUMvIARY In order to define the relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis 22 untreated patients were studied, of whom 12 were hypercalcaemic. Most patients had malabsorption of radiocalcium from the gastrointestinal tract and evidence of increased bone resorption as assessed by fasting urinary hydroxyproline/creatinine ratio.
evidence of increased bone resorption as assessed by fasting urinary hydroxyproline/creatinine ratio.
The mean OHPr/Cr ratio, however, was similar in patients with and without hypercalcaemia. Renal failure and Bence Jones proteinuria occurred more frequently in the hypercalcaemic patients.
In four patients with hypercalcaemia there was an increase in OHPr/Cr after saline infusion accompanied by an improvement in renal function and hypercalcaemia. Mithramycin given to the same patients further reduced hypercalcaemia, presumably by inhibiting bone resorption. It was concluded that the hypercalcaemia of myelomatosis is due to the combination of renal failure and increased bone resorption, but that the OHPr/Cr ratio in the untreated state is a poor indicator of the degree of bone resorption in hypercalcaemic patients.
A raised plasma calcium in patients with myelomatosis has been shown to affect prognosis adversely.' This hypercalcaemia is often attributed to excessive bone resorption, the production of which is poorly understood.
Renal failure, which is a more important prognostic factor, may be associated with and aggravated by hypercalcaemia, though renal insufficiency may be present long before there is an increase in plasma calcium.2
In order to clarify the relative importance of impaired renal function and increased bone resorption in the production of the raised plasma calcium, patients with myelomatosis have been studied and comparisons made between those with and without hypercalcaemia. We (Table 3 ) resulted in a fall in plasma calcium, a significant improvement in renal function, reduction in the renal tubular reabsorption of calcium, and an increase in calcium and hydroxyproline excretion. Mithramycin given to the same patients produced a further fall in plasma calcium within 14 hours of the infusion with a reduction in calcium and hydroxyproline excretion and no change in renal function and tubular reabsorption of calcium. The fall in urinary hydroxyproline excretion occurred within 4 hours of the start of mithramycin (Figure) .
Discussion
This study confirms the suggestion that hypercalcaemia in myelomatosis is due to a combination of increased bone resorption and renal failure.'2 While initially there was no difference in the raised hydroxyproline excretions of the normocalcaemic and hypercalcaemic patients, there was a further rise in the OHPr/Cr ratio after saline infusion in four hypercalcaemic patients. We have not studied the prolonged use of saline infusions in these patients, but in another hypercalcaemic patient who had vitamin D intoxication a similar response to saline occurred and was sustained even when renal function had ceased to improve. In the presence of pre-renal failure the OHPr/Cr ratio does not appear to correlate with the degree of bone resorption, and the increased hydroxyproline excretion after saline infusion is probably not due to increased excretion as a result of improved renal function but to abnormal renal handling of hydroxyproline. We have seen similar responses to saline infusion in other hypercalcaemias (unpublished observations). Urinary hydroxyproline, as a measurement of bone resorption in the presence of renal failure, should be used only after correction of salt and water depletion. In our hypercalcaemic patients, eight were uraemic 25 hydroxy vitamin D levels, and parathyroid hormone concentrations were normal in all but four patients. Therefore, the two factors that could possibly have caused a decrease in 1,25 dihydroxy vitamin D3 synthesis in the hypercalcaemic patients are the presence of hypercalcaemia and renal failure. The malabsorption of calcium in the patients with normal biochemistry is unexplained but may be due to the disease itself or a product of it. In two of the four patients with high plasma concentrations of parathyroid hormone, the high level could be explained by the presence of renal failure. In the other two patients, the increased concentrations may have been due to cross-reaction in the assay system by abnormal proteins.
While infusion of saline usually improves glomerular filtration rate and decreases hypercalcaemia, a normal plasma calcium is not always achieved. Mithramycin infusion in these patients produced a further decrease in plasma calcium by reducing bone resorption, as indicated by a fall in OHPr/Cr ratio. This confirms the results of Kiang et al.,18 who showed, using 85Sr or 45Ca kinetics, a reduction in bone resorption in patients with myelomatosis which occurred 6 to 12 hours after injection of mithramycin. Our data show a reduction in OHPr/Cr ratio within 4 hours of starting the infusion, and this early change suggests a direct action of the drug on bone resorption. In life-threatening hypercalcaemia, if there is an inadequate response to rehydration, it is reasonable to administer at least one infusion of mithramycin unless there is marked thrombocytopenia, which may be aggravated.
